Affinity Asset Advisors, LLC Arbutus Biopharma Corp Transaction History
Affinity Asset Advisors, LLC
- $596 Million
- Q2 2025
A detailed history of Affinity Asset Advisors, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 9,300 shares of ABUS stock, worth $41,757. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,300Holding current value
$41,757% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ABUS
# of Institutions
182Shares Held
118MCall Options Held
1MPut Options Held
478K-
Morgan Stanley New York, NY24.2MShares$108 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$59.9 Million14.31% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$51.9 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY10.4MShares$46.9 Million0.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$40.8 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $673M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...